Pancreatic ductal adenocarcinoma screening: New perspectives

World Journal of Gastroenterology

Volumn 18, Issue 36, 2012, Pages 4973-4977

  Pezzilli, Raffaele ^a   Fabbri, Dario ^a   Imbrogno, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Pancreatic neoplasms; Prevention; Study population; Therapeutics

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GELATINASE A; GELATINASE B; MICRORNA; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER RISK; CANCER SCREENING; CANCER SURGERY; CHRONIC PANCREATITIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; SENSITIVITY AND SPECIFICITY;

EID: 84867807020     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i36.4973     Document Type: Editorial

References (34)

1. Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP 2009; 10: 109-117
2. Saif MW, Sviglin H, Carpenter M. Impact of ethnicity on outcome in pancreatic carcinoma. JOP 2005; 6: 246-254
3. Mancuso A, Calabrò F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 2006; 58: 231-241
4. Gullo L, Tomassetti P, Migliori M, Casadei R, Marrano D. Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis? Pancreas 2001; 22: 210-213
5. Agency for Health care Research and Quality. Guide to Clinical Preventive Services, 2010-2011. Section 2. Recommendations for Adults. Available from: URL: http: //www. ahrq.gov/clinic/pocketgd1011/gcp10s2.htm
6. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117
7. Pezzilli R, Casadei R, Calculli L, Santini D, Morselli-Labate AM. Serum determination of CA 19-9 in diagnosing pancreatic cancer: an obituary. Dig Liver Dis 2010; 42: 73-74
8. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327
9. Goggins M. Markers of pancreatic cancer: working toward early detection. Clin Cancer Res 2011; 17: 635-637
10. Pezzilli R. Screening tests for pancreatic cancer: searching for the early symptoms or the population at risk. JOP 2004; 5: 240-242
11. Ulrich CD. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology 2001; 1: 416-422
12. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001; 1: 477-485
13. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg 2010; 44: 293-311
14. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010; 24: 349-358
15. Greenhalf W, Grocock C, Harcus M, Neoptolemos J. Screening of high-risk families for pancreatic cancer. Pancreatology 2009; 9: 215-222
16. Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25: 1417-1422
17. Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, Fishman EK, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy SV, Kalloo AN. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781; quiz 665
18. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK, Piantadosi S, Giardiello FM, Hruban RH. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621
19. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56: S82-S86
20. Carlson C, Greenhalf W, Brentnall TA. Screening of hereditary pancreatic cancer families. In: Berger HG, Bucher M, Kozarek R, Lerch M, Neoptolemos J, Warshaw A, Whitcomb D, Shiratori K, editors. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery. 2nd ed. Oxford, UK: Wiley-Blackwell Publishing, 2008: 636-642
21. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, Rothmund M, Bartsch DK. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418
22. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104: 2175-2181
23. Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, Allen PJ, Jarnagin WR, Kurtz RC. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-954
24. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6: 17-32
25. Pezzilli R, Morselli-Labate AM, Casadei R, Campana D, Rega D, Santini D, Calculli L, Corinaldesi R. Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: a prospective study. Scand J Gastroenterol 2009; 44: 888-893
26. Baine MJ, Chakraborty S, Smith LM, Mallya K, Sasson AR, Brand RE, Batra SK. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One 2011; 6: e17014
27. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208: 469-478
28. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 2011; 40: 644-652
29. Pezzilli R, Fabbri D, Corsi MM, Imbrogno A, Barassi A, Morselli-Labate AM, Dogliotti G, Casadei R, Corinaldesi R, Melzi d'Eril G. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study. Clin Chem Lab Med 2011; 49: 1047-1051
30. Pezzilli R, Corsi MM, Fabbri D, Imbrogno A, Barassi A, Morselli-Labate AM, Dogliotti G, Casadei R, Corinaldesi R, Melzi d'Eril G. Circulating metalloproteinase-3 and tissue inhibitor of metalloproteinase-2 in patients with ductal pancreatic neoplasms. J Bioscience Med 2011; 1: 1-4
31. Pezzilli R, Corsi MM, Barassi A, Morselli-Labate AM, Dogliotti G, Casadei R, Corinaldesi R, D'Eril GM. The role of inflammation in patients with intraductal mucinous neoplasm of the pancreas and in those with pancreatic adenocarcinoma. Anticancer Res 2010; 30: 3801-3805
32. Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, Dixon E, Dunse N, Sotiropoulos D, Vogel HJ. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011; 20: 140-147
33. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620
34. Harris DM, Srihari P, Go VL. Pancreatic cancer prevention and the 2010 Dietary Guidelines for Americans. Pancreas 2011; 40: 641-643